000304599 001__ 304599
000304599 005__ 20250919115032.0
000304599 0247_ $$2doi$$a10.2478/raon-2025-0047
000304599 0247_ $$2pmid$$apmid:40959926
000304599 0247_ $$2pmc$$apmc:PMC12441889
000304599 0247_ $$2ISSN$$a0485-893X
000304599 0247_ $$2ISSN$$a1318-2099
000304599 0247_ $$2ISSN$$a1581-3207
000304599 037__ $$aDKFZ-2025-01918
000304599 041__ $$aEnglish
000304599 082__ $$a610
000304599 1001_ $$aSteinberg-Vorhoff, Hannah Luisa$$b0
000304599 245__ $$aDoes volume change of the spleen correlate with the therapy response in uveal melanoma patients with liver metastases undergoing hepatic artery infusion chemotherapy?
000304599 260__ $$aWarsaw$$bSciendo$$c2025
000304599 3367_ $$2DRIVER$$aarticle
000304599 3367_ $$2DataCite$$aOutput Types/Journal article
000304599 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1758201490_22605
000304599 3367_ $$2BibTeX$$aARTICLE
000304599 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000304599 3367_ $$00$$2EndNote$$aJournal Article
000304599 520__ $$aUveal melanoma (UM) patients with liver metastases often undergo hepatic artery infusion therapy (HAIC). Due to diffuse metastatic spread in the liver, patients often develop hepatomegaly and secondary, portal hypertension which may lead to splenomegaly. This study aimed to compare spleen volumetry and the change of spleen volume (SV) for the evaluation of HAIC treatment response.In this study, 179 UM patients (mean age 64.8 ± 11.0y, 53% female) with liver metastases undergoing HAIC were included. Treatment response was analyzed by RECIST 1.1 and SV on CT imaging before and after first HAIC. The correlation of change in spleen and liver volume was analyzed with Spearman test. Overall survival (OS) was calculated as the time from the first HAIC to patient death using Kaplan-Meier test and multivariate analysis was performed for RECIST 1.1 and SV.In the study population, OS was 13.8 months (95% CI 10.6-14.7 months). Change in SV before and after first HAIC was +4% (interquartile range [IQR] -4.0%-12.0%, p = 0.49) and showed a weak correlation with OS (r = -0.11, p = 0.18). UM patients with progressive disease (PD) according to RECIST 1.1 showed an increase in SV compared to patients with stable disease (SD) (p = 0.04). Compared to RECIST 1.1, SV was not significant prognostic factor that can identify a change in OS.In uveal melanoma patients with liver metastases undergoing HAIC, neither the change of SV nor splenomegaly could be identified as prognostic factors for OS.
000304599 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000304599 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000304599 650_7 $$2Other$$ahepatic artery infusion chemotherapy
000304599 650_7 $$2Other$$aliver metastases
000304599 650_7 $$2Other$$aspleen size
000304599 650_7 $$2Other$$asurvival
000304599 650_7 $$2Other$$auveal melanoma
000304599 650_2 $$2MeSH$$aHumans
000304599 650_2 $$2MeSH$$aUveal Neoplasms: pathology
000304599 650_2 $$2MeSH$$aUveal Neoplasms: drug therapy
000304599 650_2 $$2MeSH$$aFemale
000304599 650_2 $$2MeSH$$aMelanoma: drug therapy
000304599 650_2 $$2MeSH$$aMelanoma: pathology
000304599 650_2 $$2MeSH$$aMelanoma: secondary
000304599 650_2 $$2MeSH$$aMelanoma: diagnostic imaging
000304599 650_2 $$2MeSH$$aMiddle Aged
000304599 650_2 $$2MeSH$$aMale
000304599 650_2 $$2MeSH$$aLiver Neoplasms: secondary
000304599 650_2 $$2MeSH$$aLiver Neoplasms: drug therapy
000304599 650_2 $$2MeSH$$aLiver Neoplasms: diagnostic imaging
000304599 650_2 $$2MeSH$$aInfusions, Intra-Arterial
000304599 650_2 $$2MeSH$$aSpleen: pathology
000304599 650_2 $$2MeSH$$aSpleen: diagnostic imaging
000304599 650_2 $$2MeSH$$aUveal Melanoma
000304599 650_2 $$2MeSH$$aAged
000304599 650_2 $$2MeSH$$aHepatic Artery
000304599 650_2 $$2MeSH$$aOrgan Size
000304599 650_2 $$2MeSH$$aRetrospective Studies
000304599 650_2 $$2MeSH$$aTomography, X-Ray Computed
000304599 650_2 $$2MeSH$$aTreatment Outcome
000304599 7001_ $$aDrews, Marcel$$b1
000304599 7001_ $$aOpitz, Marcel$$b2
000304599 7001_ $$aLandeghem, Natalie van$$b3
000304599 7001_ $$aSalhöfer, Luca$$b4
000304599 7001_ $$aHoltkamp, Mathias$$b5
000304599 7001_ $$aLi, Yan$$b6
000304599 7001_ $$aHaubold, Johannes$$b7
000304599 7001_ $$0P:(DE-He78)026e0a55b968f360a3c349689ce8a99c$$aSiveke, Jens$$b8$$udkfz
000304599 7001_ $$aRichly, Heike$$b9
000304599 7001_ $$aForsting, Michael$$b10
000304599 7001_ $$aSchaarschmidt, Benedikt Michael$$b11
000304599 7001_ $$aZensen, Sebastian$$b12
000304599 773__ $$0PERI:(DE-600)2134813-3$$a10.2478/raon-2025-0047$$gVol. 59, no. 3, p. 383 - 390$$n3$$p383 - 390$$tRadiology and oncology$$v59$$x1318-2099$$y2025
000304599 909CO $$ooai:inrepo02.dkfz.de:304599$$pVDB
000304599 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)026e0a55b968f360a3c349689ce8a99c$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000304599 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000304599 9141_ $$y2025
000304599 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-17
000304599 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-17
000304599 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-04-12T15:07:06Z
000304599 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-04-12T15:07:06Z
000304599 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Peer review$$d2023-04-12T15:07:06Z
000304599 915__ $$0LIC:(DE-HGF)CCBYNCNDNV$$2V:(DE-HGF)$$aCreative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND (No Version)$$bDOAJ$$d2023-04-12T15:07:06Z
000304599 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-17
000304599 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-17
000304599 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-17
000304599 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-17
000304599 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-17
000304599 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bRADIOL ONCOL : 2022$$d2024-12-17
000304599 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-17
000304599 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-17
000304599 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-17
000304599 9201_ $$0I:(DE-He78)ED01-20160331$$kED01$$lDKTK Koordinierungsstelle Essen/Düsseldorf$$x0
000304599 980__ $$ajournal
000304599 980__ $$aVDB
000304599 980__ $$aI:(DE-He78)ED01-20160331
000304599 980__ $$aUNRESTRICTED